Literature DB >> 21287222

Prophylactic surgery in Lynch syndrome.

V Celentano1, G Luglio, G Antonelli, R Tarquini, L Bucci.   

Abstract

Lynch syndrome (LS) is caused by a germline mutations in DNA mismatch repair genes and is a dominantly inherited syndrome, responsible for 2-5% of all colorectal cancer (CRC) cases. Mutation carriers have a 60-85% risk of developing CRC. With the increasing use of genetic predisposition testing, patients and health care providers must decide on cancer risk-reduction strategies. The cancers observed in families with LS are diagnosed at an unusually early age and may be multiple. The decision about which surgery is suitable should be made on the basis of patient factors and preferences, with special emphasis on age, comorbidity, sphincteric function, and the ability of the patient to cope with intensive surveillance. Colectomy decreases the risk of second CRC significantly. The estimated lifetime risk for endometrial adenocarcinoma is 40-60% in women with LS, and the mean age at diagnosis is around 50 years. This risk equals or exceeds the risk of CRC. The optimal management of the elevated risk for cancer in carriers of mutations for hereditary nonpolyposis colorectal cancer is unclear. Patients who are gene mutation carriers should receive counseling about colectomy, and if women, prophylactic hysterectomy and bilateral oophorectomy.

Entities:  

Mesh:

Year:  2011        PMID: 21287222     DOI: 10.1007/s10151-010-0666-0

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  64 in total

1.  Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction.

Authors:  K Aktan-Collan; J P Mecklin; H Järvinen; M Nyström-Lahti; P Peltomäki; I Söderling; A Uutela; A de la Chapelle; H Kääriäinen
Journal:  Int J Cancer       Date:  2000-01-20       Impact factor: 7.396

2.  Prophylactic surgery prevents endometrial and ovarian cancer in Lynch syndrome.

Authors:  Henry T Lynch; Murray Joseph Casey
Journal:  Nat Clin Pract Oncol       Date:  2007-10-30

3.  Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families.

Authors:  Wouter H de Vos tot Nederveen Cappel; Fokko M Nagengast; Gerrit Griffioen; Fred H Menko; Babs G Taal; Jan H Kleibeuker; Hans F Vasen
Journal:  Dis Colon Rectum       Date:  2002-12       Impact factor: 4.585

4.  Histopathology of colorectal carcinomas and adenomas in cancer family syndrome.

Authors:  J P Mecklin; P Sipponen; H J Järvinen
Journal:  Dis Colon Rectum       Date:  1986-12       Impact factor: 4.585

5.  Screening behavior of individuals at high risk for colorectal cancer.

Authors:  Eveline M A Bleiker; Fred H Menko; Babs G Taal; Irma Kluijt; Lidwina D V Wever; Miranda A Gerritsma; Hans F A Vasen; Neil K Aaronson
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

6.  Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.

Authors:  Jens Plaschke; Christoph Engel; Stefan Krüger; Elke Holinski-Feder; Constanze Pagenstecher; Elisabeth Mangold; Gabriela Moeslein; Karsten Schulmann; Johannes Gebert; Magnus von Knebel Doeberitz; Josef Rüschoff; Markus Loeffler; Hans K Schackert
Journal:  J Clin Oncol       Date:  2004-10-13       Impact factor: 44.544

7.  Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum.

Authors:  Claudio Soravia; Heleen van der Klift; Marie-Anne Bründler; Jean-Louis Blouin; Juul Wijnen; Pierre Hutter; Riccardo Fodde; Célia Delozier-Blanchet
Journal:  Am J Med Genet A       Date:  2003-08-30       Impact factor: 2.802

8.  Iatrogenic perforation associated with therapeutic colonoscopy: a multicenter study in Japan.

Authors:  Keisei Taku; Yasushi Sano; Kuang-I Fu; Yutaka Saito; Takahisa Matsuda; Toshio Uraoka; Takayuki Yoshino; Yuichirou Yamaguchi; Mikio Fujita; Santa Hattori; Tsutomu Ishikawa; Daizo Saito; Takahiro Fujii; Eizo Kaneko; Shigeaki Yoshida
Journal:  J Gastroenterol Hepatol       Date:  2007-06-25       Impact factor: 4.029

9.  Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families.

Authors:  Siobhan S Wahlberg; James Schmeits; George Thomas; Massimo Loda; Judy Garber; Sapna Syngal; Richard D Kolodner; Edward Fox
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

10.  Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.

Authors:  H F Vasen; J T Wijnen; F H Menko; J H Kleibeuker; B G Taal; G Griffioen; F M Nagengast; E H Meijers-Heijboer; L Bertario; L Varesco; M L Bisgaard; J Mohr; R Fodde; P M Khan
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

View more
  5 in total

1.  Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update 2012.

Authors:  Nils Rahner; Verena Steinke; Brigitte Schlegelberger; Francois Eisinger; Pierre Hutter; Sylviane Olschwang
Journal:  Eur J Hum Genet       Date:  2012-08-15       Impact factor: 4.246

Review 2.  The evolution of colorectal cancer genetics-Part 2: clinical implications and applications.

Authors:  Andrew T Schlussel; Ronald A Gagliano; Susan Seto-Donlon; Faye Eggerding; Timothy Donlon; Jeffrey Berenberg; Henry T Lynch
Journal:  J Gastrointest Oncol       Date:  2014-10

Review 3.  Advances in the study of Lynch syndrome in China.

Authors:  Jun-Yu Lu; Jian-Qiu Sheng
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

4.  Endoscopic and surgical management of hereditary nonpolyposis colorectal cancer.

Authors:  Rebeccah B Baucom; Paul E Wise
Journal:  Clin Colon Rectal Surg       Date:  2012-06

Review 5.  Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?

Authors:  Davide Angeli; Samanta Salvi; Gianluca Tedaldi
Journal:  Int J Mol Sci       Date:  2020-02-08       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.